Covid-19 Impact on Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market Outlook:

The global myasthenia gravis treatment market is experiencing a major growth, and will grow considerably in next few years. Myasthenia gravis is a disorder likely to weaken the skeletal muscles of the body uses for movement. In myasthenia gravis, the immune system disrupts the transmission of nerve impulses to muscles by producing antibodies that binds to proteins important for nerve signal transmission. Antibodies normally bind to specific foreign particles and germs, marking them for destruction, but the antibody in myasthenia gravis attacks a normal human protein. In most affected individuals, the antibody targets a protein called acetylcholine receptor (AChR), in others, the antibodies attack a related protein called muscle-specific kinase (MuSK). In both cases, the abnormal antibodies lead to a reduction of available AChR.

Market scope and structure analysis:

Report Metric

Details

  Market size available for years

  2019–2027

  Base year considered

  2019

  Forecast period

  2020–2027

  Forecast units

  Value (USD)

  Segments covered

  Medication type, distribution channel and Region

  Geographies covered

North America (US and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia Pacific (China, Japan, India, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM) and The Middle East and Africa

  Companies covered

Major players analyzed include Alexion Pharmaceutical Inc., GlaxoSmithKline plc, Grifols SA, F. Hoffmann-La Roche Ltd, Avadel Pharmaceuticals plc, Pfizer, Inc., Novartis AG, AbbVie Inc., Bausch Health Companies Inc., and Shire plc.

 

Request Report Sample- https://www.alliedmarketresearch.com/request-toc-and-sample/11559

COVID-19 scenario analysis:

  • Increase in the incidences of Covid-19 has resulted each day, has resulted in the need of covid-19 vaccine across the globe. Therefore leading to rise in demand research and development. Due to increase in Covid-19 research the other researches and clinical trials has slowed sown which has impacted the growth of the myasthenia gravis treatment market.
  • There is evidence by some research that the Covid patients having myasthenia gravis patients earlier are experience some pain.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Increase in attention towards research and development, rapidly increasing population with myasthenia gravis in emerging countries and surge in geriatric population with autoimmune disease are major factor driving the growth of the myasthenia gravis market. However, high dose combination is responsible for severe muscle cramps in myasthenia gravis patients can hinder the market growth. On the contrary, increase in number of clinical trials for treatment of myasthenia gravis is expected to propel the myasthenia gravis treatment market growth during the forecast period.

The global myasthenia gravis treatment market trends are as follows:

New product launches and awareness campaigns to flourish the market

The need for launches of new products and constant innovations has tremendously driven the market growth. For instance, in June 2020, Argenx launched its first awareness efforts for autoimmune disease myasthenia gravis. The campaign began recently with a virtual conference, light-up nights around the country, a patient website debut and the promise of an upcoming documentary. Further, increase in clinical trials is expected to drive the market growth. For instance, Argenx BVBA is conducting a clinical phase III study of ARGX-113 for treatment of generalized myasthenia gravis. ARGX-113, also named Efgartigimod, is administered intravenously. The study started in March 2019 and is expected to be completed in June 2021.

Speak to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/11559

Key segments covered:

Segments

Sub-segments

  Medication type

  • Cholinesterase inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Others

  Distribution channel

  • Hospital pharmacies
  • Retail pharmacies
  • Others

Key benefits of the report:

  • This study presents the analytical depiction of the global myasthenia gravis treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global myasthenia gravis treatment market share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global myasthenia gravis treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides detailed global myasthenia gravis treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Myasthenia gravis treatment market research report:

  • What are the leading market players active in the myasthenia gravis treatment market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

Read more- https://www.alliedmarketresearch.com/myasthenia-gravis-treatment-market-A11194

Leave a Reply

Your email address will not be published. Required fields are marked *